COVID, SARS-CoV 2
Conditions
Keywords
SARS-CoV-2, prevalence, asymptomatic infection, spread dynamics
Brief summary
The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on direct detection of SARS-CoV- 2, including individuals with a subclinical course of the disease.
Detailed description
COVID-19 is caused by a new type of coronavirus called SARS-CoV-2. It is a highly infectious disease, manifested mainly by fever, respiratory problems, muscle pain, and fatigue. However, despite the publication of hundreds of papers in the literature, fundamental information about the spread and course of the disease is still lacking in COVID-19. One of such key pieces of information is the prevalence of asymptomatic individuals with SARS-CoV-2 infection, which has a significant effect on the dynamics of the spread of COVID-19 in the Czech Republic and within individual regions and localities. The SARS-CoV-2-CZ-Preval study is aiming at quantification of the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on direct detection of SARS-CoV- 2, including individuals with a subclinical course of the disease.
Interventions
DIAGNOSTIC_TESTSARS-CoV-2 diagnostic rapid test
The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
DIAGNOSTIC_TESTQuantitative analysis of SARS-CoV-2 antibodies
The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
Sponsors
Ministry of Health, Czech Republic
Palacky University
Masaryk University
University of Ostrava
Faculty of Military Health Sciences, University of Defence in Brno
Faculty of Health Studies, J. E. Purkyně University in Ústí nad Labem
Charles University, Czech Republic
Institute for Clinical and Experimental Medicine
General University Hospital, Prague
University Hospital Olomouc
Brno University Hospital
Krajská zdravotní, a.s., Ústí nad Labem Region Hospitals
Military University Hospital, Prague
Masaryk Memorial Cancer Institute
Czech Academy of Sciences
Czech Statistical Office
Institute of Health Information and Statistics of the Czech Republic
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
8 Years to 89 Years
Healthy volunteers
Yes
Inclusion criteria
* signed Informed Consent * residing in The Czech Republic * demographic criteria: (i) persons aged 8-17 (specific children's cohort), (ii) persons aged 18-89 * clinical criteria: (i) without acute health problems (ii) without a confirmed diagnosis of COVID-19 * geographic criteria: according to a particular cohort definition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic. | May 2020 | Statistically, the primary objective is formulated as an estimate of the cumulative prevalence of SARS-CoV-2 positive individuals in geographically defined subpopulations of the Czech Republic with declared reliability of +/- 2%. For this primary objective, the required sample size in individual geographical cohorts is calculated. The positivity of SARS-CoV-2 individuals who have not been diagnosed with COVID-19 by a standard route of the detection will be assessed by the presence of specific IgM or IgG antibodies in the blood (antibody tests). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of the proportion of people with a subclinical course of the disease | May 2020 | The proportion of SARS-CoV-2 positive persons who, according to the questionnaire, will not report any or minimal symptoms in the anamnesis. |
| Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications. | May 2020 | — |
| Estimation of the proportion of persons suitable for the donation of convalescent plasma | May 2020 | The estimation will be calculated according to the prevalence of the disease in the population after excluding contraindications to blood donation (age, health status, etc.). |
Countries
Czechia
Outcome results
None listed